Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,807.70
13.50 (0.75%)
Medium VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹4.34L Cr
LARGE CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
37.2
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹1,548+16.8%
52W High₹1,916.6-5.7%
Current Price
₹1,807.70
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,446.16
Upper Circuit₹2,169.24
Reference Price
₹1,807.70
Investment Checklist
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹1826.6
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹1788.2
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Composite score 48.03 (BUY) with 88.9% confidence
Volume divergence: Bearish (price up, volume down)
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
89%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
1804.78
EMA50
1789.57
EMA200
1732.58
Price Action
CONSOLIDATION
NEUTRAL
Higher Highs5
Higher Lows5
Lower Highs4
Lower Lows4
Support & Resistance Levels
Resistance (Above)
₹1814.87
₹1846.00
₹1916.60
Support (Below)
₹1682.34
₹1564.72
Volume Analysis
TrendDECREASING
Change-18.90%
Unusual VolumeNo
Divergence Detected
Bearish (price up, volume down)
Stop Loss Levels
Fixed Risk
1% Risk₹1789.62
3% Risk₹1753.47
5% Risk₹1717.32
7% Risk (Custom)
₹1681.16Technical Levels
1x ATR (Volatility)₹1771.98
2x ATR (Swing)₹1736.26
3x ATR (Trend)₹1700.54
Immediate Support₹1682.34
Moving Averages
EMA 9 (Short-term)₹1797.24
EMA 20 (Medium-term)₹1804.78
EMA 50 (Trend)₹1789.57
EMA 200 (Long-term)₹1732.58
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹13,436.9 Cr | ₹12,815.6 Cr | ₹13,786.1 Cr | ₹15,469.1 Cr |
| Net Profit | ₹2,903.4 Cr | ₹2,149.9 Cr | ₹2,278.6 Cr | ₹3,368.8 Cr |
| EPS | ₹12.10 | — | ₹9.50 | ₹14.00 |
| Operating Profit | ₹4,158.5 Cr | ₹3,967.3 Cr | ₹3,948.1 Cr | ₹5,037.9 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
| BIOCON | Biocon Limited | ₹419.00 | +0.73% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 05 Feb 2026 | Interim Dividend - Rs 11 Per Share | INTERIM_DIVIDEND |
| 07 Jul 2025 | Dividend - Rs 5.50 Per Share | DIVIDEND |
| 06 Feb 2025 | Interim Dividend - Rs 10.50 Per Share | INTERIM_DIVIDEND |
| 12 Jul 2024 | Dividend - Rs 5 Per Share | DIVIDEND |
| 09 Feb 2024 | Interim Dividend - Rs 8.50 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for SUNPHARMA
View AllNEWS
positive
Business Standard - Markets 1d ago
Sun Pharmaceutical Industries fixes record date for final dividend
Record date is 07 July 2026
DIVIDENDSUNPHARMAFinancial ServicesHealthcare
positive
ET Markets - Stocks 3d ago
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
ABCAPITALABFRLABGSECABLBLABRELABSL10BANKABSLAMCABSLBANETFABSLLIQUIDABSLNN50ETABSLPSEAJANTPHARMALPHAALPHAETFAONEGOLDAONELIQUIDAONENIFTYAONESILVERAONETOTALAUTOBEESAUTOIETFAXISBNKETFAXISBPSETFAXISCETFAXISGOLDAXISHCETFAXISILVERAXISNIFTYAXISTECETFAXISVALUEAXSENSEXBANK10ADDBANKADDBANKBETFBANKETFBANKPSUBBETF0432BBNPNBETFBBNPPGOLDBFSIBIRLACORPNBIRLAMONEYBSLGOLDETFBSLNIFTYBSLSENETFGCHEMICALCHOICEGOLDCOMMOIETFDEFENCEDIVIDENDEBANKNIFTYEBBETF0430EBBETF0431EBBETF0433ECAPINSUREEGOLDELIQUIDELM250ENERGYENIFTYEQUAL200EQUAL50EQUAL50ADDESENSEXESGESILVERFINIETFFLEXIADDFMCGADDFMCGIETFGILT10BETAGILT5BETAGOLD1GOLD360GOLDADDGOLDBETAGOLDBNDGOLDETFGROWWCAPMGROWWCHEMGROWWDEFNCGROWWEVGROWWGOLDGROWWHOSPIGROWWLIQIDGROWWLOVOLGROWWMC150GROWWMETALGROWWMOM50GROWWN200GROWWNETGROWWNIFTYGROWWNXT50GROWWPOWERGROWWPSEGROWWPSUBKGROWWRAILGROWWRLTYGROWWSC250GROWWSLVRGSEC10ABSLGSEC10IETFGSEC10YEARHDFCGOLDHDFCGROWTHHDFCLOWVOLHDFCMID150HDFCMOMENTHDFCNEXT50HDFCNIF100HDFCNIFITHDFCPSUBKHDFCPVTBANHDFCQUALHDFCSILVERHDFCSML250HDFCVALUEHEALTHADDHEALTHCAREHEALTHIETFHEALTHYHSBCGOLDICICIB22INFRAIETFINTERNETITADDITBEESITBETAITETFITIETFKOTAKBANKLICNETFSENLICNMID100LIQGRWBEESLIQUIDLIQUID1LIQUIDPLUSLIQUIDSBILIQUIDSHRILOWVOLMAFANGMAHKTECHMAKEINDIAMANUFGBEESMASPTOP50METALMETALIETFMID150MIDCAPADDMIDCAPBETAMIDCAPETFMIDCAPIETFMIDQ50ADDM&MMNCMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM30IETFMOM50MOMENTUMMOMENTUM30MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTOURMOVALUEMSCIADDMSCIINDIAMULTICAPNEXT30ADDNEXT50NEXT50ADDNEXT50BETANEXT50ETFNEXT50IETFNIFTY100EWNIFTYADDNIFTYBETFNIFTYETFNIFTYQLITYOILIETFPHARMABEESPSUBANKADDPSUBNKIETFPVTBANKADDQUALITY30SBIBPBSBIETFCONSBIETFITSBIETFPBSBIETFQLTYSBILIQETFSBINEQWETFSBINMID150SBISILVERSELECTIPOSENSEXETFSETF10GILTSILVERSILVER1SILVER360SILVERADDSILVERAGSILVERBEESSILVERBETASILVERBNDSILVERIETFSMALL250SMALLADDSNXT30BEESSPARCSUNPHARMATATAGOLDTATSILVTECHTNIDETFTOP10ADDTOP20TWCGOLDETFUNIONGOLDVAL30IETFVALUEAutomobile and Auto ComponentsConstruction Materials
positive
ET Markets - Industry 4d ago
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.
ABSL10BANKABSLBANETFABSLPSEAXISBNKETFBANK10ADDBANKADDBANKBETFBANKETFBANKINDIABANKPSUBBNPNBETFEBANKNIFTYFINIETFGLOBALGROWWPSUBKHDFCPSUBKHDFCPVTBANINDIANBIOBLIQUIDSBIMOBANK10MOMENTUMNIFTYQLITYNPBETPHARMABEESPSUBANKADDPSUBNKIETFPVTBANKADDSBIBPBSBIETFCONSBIETFITSBIETFPBSBIETFQLTYSBILIQETFSBINSBINEQWETFSBINMID150SBISILVERSETF10GILTSETFNIFBKSILVERSOUTHBANKSPARCSUNPHARMATECHConsumer ServicesFinancial Services